Description
Key facts
Detection method:Colorimetric,
Sample types:Heparin Plasma, Citrate plasma, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 8 pg/mL,
Range:31.25 - 2000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Human ABO ELISA Kit (Histo-Blood Group ABO System Transferase) (ab270207) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of ABO (Histo-Blood Group ABO System Transferase) protein in edta plasma, serum, cit plasma, and hep plasma. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human ABO (Histo-Blood Group ABO System Transferase) with 8 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
ABO, Histo-Blood Group ABO System Transferase, is a glucosyltransferase that is the key determinant of an individual’s blood type. This enzyme transfers UDP-GalNAC or UDP-Gal to H-antigen which results in A, B, or AB blood type. The antibodies for this kit were raised against recombinant protein representing the lumenal domain of the mature protein. The immunogen for this kit does not share high sequence similarity with mouse or rat ABO protein and is not expected to cross-react. However, this protein is homologous to primate ABO.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ABO blood group system frequently referred to as ABO is a critical component in determining blood type. It involves the presence of antigens on the surface of red blood cells which are glycosyltransferase enzymes that transfer sugar residues onto the H antigen. The gene responsible for this system is located on chromosome 9 and the variations in the gene produce the A B and O blood types. These glycoproteins and glycolipids confer blood group specificity. ABO is found in the erythrocytic lineage and is an integral part of the blood plasma context.
Biological function summary
The ABO proteins modulate immune response mechanisms. They participate in the formation of specific antigens and antibodies that define the ABO blood group system. These proteins are not part of a larger complex but interact closely with components in the immune system. In individuals the presence or absence of antigen types influences immune activity and the antigen-antibody structure is essential in transfusion medicine.
Pathways
Researchers link the ABO system with several immune response pathways. The system integrates into the complement system and humoral immunity affecting compatibility in blood transfusions. It is indirectly related to proteins in the complement cascade and these interactions facilitate or hinder immune reactions during transfusions and organ transplants. The pathway involvement highlights the system’s significance in cellular communication and immune mobilization.
ABO incompatibility can lead to hemolytic disease of the newborn and transfusion reactions. In such contexts the presence of incompatible ABO antigens triggers immune responses resulting in adverse events. It also indirectly connects to diseases like gastric cancer where blood type prevalence indicates varying disease risk profiles. The interaction with proteins such as the Rh factor can exacerbate these conditions showing how ABO status affects susceptibility and symptom severity.
